Current treatment strategies for chronic hepatitis B and C

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 29-49

  Lin, O S ^a   Keeffe, E B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Genotype; Interferon; Lamivudine; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; AMINOTRANSFERASE; COTRIMOXAZOLE; ENZYME INHIBITOR; HELICASE INHIBITOR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; LAMIVUDINE; MACROGOL; PREDNISONE; PROTEINASE INHIBITOR; RIBAVIRIN; RIBOZYME; RIMANTADINE; SILYMARIN; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CHRONIC HEPATITIS; COMORBIDITY; DRUG FORMULATION; DRUG MEGADOSE; ENZYME BLOOD LEVEL; ETHNIC DIFFERENCE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; SILYBUM MARIANUM; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; LIFE STYLE; RIBAVIRIN; TREATMENT OUTCOME; VACCINATION;

EID: 0035126864     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.29     Document Type: Article

References (100)

1. Hepatitis B virus infection
2. The treatment of chronic viral hepatitis
3. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
4. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa
5. Hepatolog cost comparison of interferon and lamivudine for the treatment of chronic hepatitis B
6. Vaccination against hepatitis A and B in chronic liver disease
7. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment
8. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
9. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
10. Effect of alpha-interferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B. A metaanalysis
11. Cost-effectiveness of interferonalpha 2b treatment for hepatitis B e antigenpositive chronic hepatitis B
12. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial
13. Long-term remission of chronic hepatitis B after alpha-interferon therapy
14. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy
15. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa
16. Which patients with chronic hepatitis B virus infection will respond to alphainterferon therapy? A statistical analysis of predictive factors
17. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
18. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
19. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B
20. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a
21. A one-year trial of lamivudine for chronic hepatitis B
22. Lamivudine as initial treatment for chronic hepatitis B in the United States
23. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
24. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial
25. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine
26. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
27. Three year lamivudine therapy in chronic HBV
28. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
29. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
30. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
31. End-stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B
32. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation
33. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients
34. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
35. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial
36. Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population
37. Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population
38. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
39. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients
40. Lamivudine for chronic delta hepatitis
41. Treatment of chronic hepatitis D with interferon alfa-2a
42. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial
43. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: A multicenter Italian study
44. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: Utility of polymerase chain reaction in monitoring antiviral response
45. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment
46. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy
47. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
48. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
49. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg
50. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon
51. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
52. Beneficial effect of lamivudine pre- and post-liver transplantation for hepatitis B infection
53. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
54. Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation
55. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
56. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
57. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
58. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
59. Hepatitis B vaccine in medical staff of hemodialysis units: Efficacy and sub-type cross-protection
60. Susceptibility of lamivudineresistant hepatitis B virus to other reverse transcriptase inhibitors
61. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
62. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
63. Epidemiology of hepatitis C
64. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
65. 45-year follow-up of hepatitis C virus infection in healthy young adults
66. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions
67. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
68. EASL International Consensus Conference on Hepatitis C. Paris, February 26-28, Consensus Statement. European Association for the Study of the Liver
69. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs
70. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C
71. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
72. Use of high-dose interferon in the treatment of chronic hepatitis C
73. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
74. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
75. Randomised, double-blind, placebocontrolled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
76. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
77. 10-Year follow-up after interferon alpha therapy for chronic hepatitis C
78. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial
79. Re-treatment of chronic hepatitis C with consensus interferon
80. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C
81. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
82. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon
83. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
84. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
85. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
86. Racial differences in responses to therapy with interferon in chronic hepatitis C
87. Future options for the management of hepatitis C
88. Evaluation of the safety and efficacy of once-weekly PEG/interferon alfa-2a (Pegasys™) for chronic hepatitis C. A multinational, randomized study
89. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C
90. Combination therapy with peginterferon alpha-2a (PEGIFN) and ribavirin in the treatment of patients with chronic hepatitis C: A phase II open label study
91. Milk thistle (Silybum marianum) for the therapy of liver disease
92. Treatment of chronic hepatitis C with amantadine
93. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C
94. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy
95. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha nonresponders
96. Interferon alpha-2a in combination with ribavirin and amantadine (triple therapy) in hepatitis C patients with previous nonresponse to interferon alpha and ribavirin combination therapy
97. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
98. Inhibition of hepatitis C virus (HCV) RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
99. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts